The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: Lessons learned from infantile Pompe disease
Top Cited Papers
- 1 August 2011
- journal article
- research article
- Published by Elsevier BV in Genetics in Medicine
- Vol. 13 (8), 729-736
- https://doi.org/10.1097/gim.0b013e3182174703
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infantsMolecular Genetics and Metabolism, 2010
- Early Treatment With Alglucosidase Alfa Prolongs Long-Term Survival of Infants With Pompe DiseasePediatric Research, 2009
- Immune response to enzyme replacement therapy in Fabry disease: Impact on clinical outcome?Molecular Genetics and Metabolism, 2009
- How we treat a hemophilia A patient with a factor VIII inhibitorBlood, 2009
- Treatment of Fabry disease with different dosing regimens of agalsidase: Effects on antibody formation and GL-3Molecular Genetics and Metabolism, 2008
- Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis IJCI Insight, 2008
- Enhanced Response to Enzyme Replacement Therapy in Pompe Disease after the Induction of Immune ToleranceAmerican Journal of Human Genetics, 2007
- Differential muscular glycogen clearance after enzyme replacement therapy in a mouse model of Pompe diseaseMolecular Genetics and Metabolism, 2007
- Chinese hamster ovary cell-derived recombinant human acid α-glucosidase in infantile-onset Pompe diseaseThe Journal of Pediatrics, 2006
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958